Welcome to our dedicated page for bioAffinity Tech SEC filings (Ticker: BIAF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
bioAffinity Technologies, Inc. SEC filings document the public-company record for a biotechnology diagnostics issuer with Nasdaq-listed common stock and tradeable warrants. The filings identify the company as an emerging growth company and smaller reporting company and include disclosures tied to CyPath® Lung, laboratory services, operating performance, and securities registration activity.
Recent filings include Form 8-K reports for financial results, Regulation FD presentation materials, product and clinical-case announcements, and annual meeting voting results. The record also covers governance matters such as director elections and equity incentive plan amendments, along with S-1 registration materials describing securities being registered and related issuer classifications.
bioAffinity Technologies, Inc. reported a new clinical case study evaluating its noninvasive CyPath® Lung test in a high-risk patient with multiple lung nodules. The company furnished a press release describing how the test result helped guide care and potentially avoid an invasive lung procedure.
The 71‑year‑old former smoker had several pulmonary nodules, including a 7 millimeter nodule that might normally trigger bronchoscopy or biopsy. A CyPath® Lung result indicating unlikely malignancy supported the pulmonologist’s decision to monitor with a follow‑up CT scan instead of immediately ordering an invasive procedure.
The follow‑up scan showed suspicious nodules had resolved, suggesting benign inflammation, while one small nodule remained stable. The press release notes prior clinical study performance for CyPath® Lung, with 92% sensitivity, 87% specificity and 88% accuracy for detecting lung cancer in high‑risk patients with small nodules under 20 millimeters.
bioAffinity Technologies is asking stockholders at its April 30, 2026 annual meeting to approve a broad set of governance and financing proposals. These include electing six directors and ratifying WithumSmith+Brown, PC as auditor for the year ending December 31, 2026.
The proxy also seeks approval for issuing up to 271,500 shares upon exercise of August 2025 warrants and related anti-dilution adjustments that could increase warrant and Series B preferred share issuances. The Board requests authorization for non‑public offerings, potential change of control under Nasdaq rules, a 1‑for‑2 to 1‑for‑250 reverse stock split at the Board’s discretion, and an adjournment option.
In addition, the company proposes amending its 2024 Equity Incentive Plan to raise the share reserve from 66,666 to 1,000,000 shares, citing the need to attract and retain key employees and directors while aligning compensation with stockholder interests.
bioAffinity Technologies, Inc. files its annual report describing a lung cancer diagnostics and therapeutics business built around its CyPath® Lung test and flow cytometry + AI platform.
For the year ended December 31, 2025, consolidated revenue fell about 34% to $6.2 million from $9.4 million as the Company discontinued unprofitable pathology services and focused operations. CyPath® Lung testing revenue grew about 87% to $963,000, driven by a 99% increase to more than 1,200 test results.
The Company emphasizes that its business plan depends on securing additional capital and explicitly notes it must raise more funds to continue as a going concern. In 2025 it raised roughly $16.9 million in gross proceeds through multiple public, private and warrant-related equity transactions. As of June 30, 2025, non‑affiliate equity market value was approximately $22.6 million, and shares outstanding were 4,498,675 as of March 13, 2026.
bioAffinity highlights progress on a large longitudinal lung cancer trial, new military collaborations, early asthma/COPD companion diagnostic research, and an oncology therapeutic platform, supported by a portfolio of 19 issued patents and numerous pending applications worldwide.
bioAffinity Technologies reported 2025 results showing rapid growth in its CyPath® Lung lung cancer test but a wider overall loss. Revenue from CyPath® Lung testing rose 87% year over year, with the number of tests up 99% and ordering physician sites up 67%, reflecting stronger clinical adoption.
Total 2025 revenue was $6.2 million, down from $9.4 million in 2024 after discontinuing unprofitable pathology services. Operating expenses fell 9% to $16.7 million, but the net loss widened to $14.9 million from $9.0 million, mainly due to a non-cash change in warrant fair value and higher commercial and clinical spending.
Cash and cash equivalents increased to $6.5 million as of December 31, 2025, from $1.1 million a year earlier, supported by $16.9 million raised in 2025 financings. The company forecasts CyPath® Lung unit sales growth of more than 100% in 2026 and is running a longitudinal trial targeting up to 2,000 high-risk patients to further validate the test.
bioAffinity Technologies has begun a large, 2,000-patient longitudinal clinical study of CyPath® Lung, its noninvasive sputum-based test for early-stage lung cancer detection in high-risk patients with lung nodules 6 to less than 30 millimeters.
The study will run across up to 20 sites, including numerous VA medical centers and major military hospitals, with patients followed for up to 24 months or until a definitive cancer or no-cancer diagnosis. An earlier trial showed 92% sensitivity, 87% specificity and 88% accuracy in high-risk patients with nodules less than 20 millimeters.
The new trial, supported in part by the John P. Murtha Cancer Center Research Program, uses a research-use version called FlowPath Lung that applies the same flow cytometry and AI technology as the commercially available CyPath® Lung Laboratory Developed Test.
bioAffinity Technologies, Inc. reported that directors Robert Anderson and Roby Joyce have chosen not to stand for re-election when their current terms expire at the company’s 2026 Annual Meeting of Stockholders, currently scheduled for April 30, 2026.
The company stated that the decisions by Mr. Anderson and Mr. Joyce are not due to any disagreements with bioAffinity Technologies regarding its operations, policies, or practices. Both will continue to serve as directors until their terms end at the 2026 Annual Meeting.
bioAffinity Technologies is soliciting proxies for its Annual Meeting on April 30, 2026. The Company asks stockholders to elect six directors and ratify WithumSmith+Brown, PC as auditor. Key voting items seek approval to issue up to 271,500 shares on exercise of August 2025 warrants; approve a warrant anti-dilution adjustment increasing potential warrant shares to 365,620; approve a Series B anti-dilution adjustment increasing potential conversion shares to 131,884; amend the 2024 Equity Incentive Plan to reserve 1,000,000 shares (up from 66,666); authorize non-public offerings and related change-of-control approval under Nasdaq rules; and approve a reverse stock split at a ratio of 1-for-2 to 1-for-250 at the Board’s discretion.
The proxy materials explain voting mechanics, quorum and vote thresholds, broker non-vote treatments, and includes the Board’s FOR recommendations on all proposals.
bioAffinity Technologies, Inc. reported that it presented a scientific poster titled “Sputum as a Diagnostic Tool for the Treatment of Asthma” at the 2026 American Academy of Allergy, Asthma and Immunology meeting in Philadelphia. The work highlights a noninvasive sputum-based diagnostic approach.
The research describes using bioAffinity’s platform to identify antibody drug receptors in sputum for asthma and COPD therapies, including dupilumab and benralizumab, to help match patients with effective biologic treatments and monitor inflammatory changes. The company notes this platform underpins its commercial CyPath® Lung test, which in clinical studies showed 92% sensitivity, 87% specificity and 88% accuracy for early lung cancer detection.
bioAffinity Technologies, Inc. is launching a validation study with Brooke Army Medical Center to test its CyPath® Lung diagnostic on sputum samples collected through tracheal and bronchial suctioning for early lung cancer detection. The study will enroll about 30–50 patients undergoing routine suction procedures, with results expected by mid-year 2026.
CyPath® Lung is a noninvasive test that uses flow cytometry, AI, and a fluorescent porphyrin to identify malignant cell populations in sputum. Prior clinical results showed 92% sensitivity, 87% specificity, and 88% accuracy in high-risk patients with small lung nodules.
The study aims to expand sample collection options beyond at-home sputum collection and leverage bronchoscopy procedures, which are performed roughly 500,000 times annually in the U.S. The company highlights a U.S. bronchoscopy-related market estimated at $700–$920 million and positions this work as a step toward broader use of CyPath® Lung.